Evidence map›Paper›PMID 35186121›Full record

ArticleTherapeutic advances in gastroenterology2022

Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.

Maria Lia Scribano, Annalisa Aratari, Benedetto Neri, Cristina Bezzio, Paola Balestrieri, Valentina Baccolini, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Rita Monterubbianesi and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Maria Lia ScribanoGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Rome, Italy.ORCID https://orcid.org/0000-0003-1839-8136
Annalisa AratariIBD Unit, San Filippo Neri Hospital, Rome, Italy.
Benedetto NeriGastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Cristina BezzioGastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.
Paola BalestrieriGastroenterology Unit, Campus Bio-Medico University, Rome, Italy.
Valentina BaccoliniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Giuliano FalascoGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Caterina CamastraGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Paolo PantanellaGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Rita MonterubbianesiGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Alessandro TullioGastroenterology Unit, Campus Bio-Medico University, Rome, Italy.
Simone SaibeniGastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.
Claudio PapiIBD Unit, San Filippo Neri Hospital, Rome, Italy.
Livia BianconeGastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Rocco CosintinoGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Roberto FaggianiGastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Azienda Ospedaliera San Camillo-Forlanini · ITAziende Socio Sanitaria Territoriale RhodenseOspedale San Filippo Neri · ITUniversità Campus Bio-Medico · ITUniversity of Rome Tor Vergata · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effectiveness of ustekinumab in patients with refractory Crohn's disease (CD) has been investigated in several real-world studies. However, very few data concerning the real-life experience in Italy have been reported. Therefore, this study assessed the effectiveness of ustekinumab in a large cohort of Italian patients with refractory CD.

methodsAll patients who had started on ustekinumab after failure of or intolerance to antitumour necrosis factor-α (TNF-α) treatment at five tertiary centres between November 2018 and February 2020 were retrospectively enrolled. The coprimary outcome was corticosteroid-free clinical remission, defined as a Harvey-Bradshaw Index (HBI) score of ⩽4, at weeks 26 and 52. The secondary outcomes were changes in the HBI and C-reactive protein (CRP) values at weeks 8, 26, and 52 from baseline and the normalization of CRP in patients with initially abnormal values.

resultsTotally, 140 patients who had previously received at least one anti-TNF-α agent were enrolled; 40.0% received two anti-TNF-α agents and 20.0% received vedolizumab. At baseline, 108 patients (77.1%) had HBI scores of >4; of these, 56.5% and 58.3% achieved corticosteroid-free clinical remission at weeks 26 and 52, respectively. Significant decreases in HBI and CRP values were observed at weeks 8, 26, and 52 in the entire study cohort (all

conclusionOur study findings confirm the effectiveness and safety of ustekinumab in patients with CD after failure of or intolerance to anti-TNF-α therapy.

Indexed as

Crohn’s diseaseeffectivenessrefractoryustekinumab

Identifiers

PMID35186121
PMCPMC8848093
OpenAlexW4213101964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.